Multiparameter flow cytometry may be used to detect minimal residual disease in acute leukemia because leukemic cells often display aberrant phenotypes when compared to normal cells. One limitation of this approach in B-precursor ALL is that leukemic phenotypes are often qualitatively similar to normal marrow B progenitors, though it has long been recognized that the latter show a predictable pattern of antigen expression with differentiation. In this study we used four-color flow cytometry to define precisely the patterns of normal antigen expression on a series of normal bone marrows using two different four-color combinations of antibodies: CD19-APC/CD45-perCP/CD20-PE/CD10-FITC; and CD19-APC/CD45-perCP/CD9-PE/CD34-FITC. A series of dual parameter displays were created in which normal B precursors occupied predictable regions. We then tested these antibody combinations on a series of 82 cases of B-precursor ALL and found that in 76/82 cases (93%) the first combination demonstrated an abnormal population on at least one of the dual parameter displays, and that 72/77 cases tested (94%) showed an abnormality with the second combination. When taken together, 81/82 cases (99%) showed an abnormality. When purified blasts were serially diluted into normal marrows we found a sensitivity of detection of 1 cell in 10 4 normal marrow cells provided sufficient CD19 + cells were acquired to visualize the abnormal population as a discrete cluster. Because the pattern of antigen expression in normals is very reproducible, it is possible to create a fixed set of geometrical regions to define the normal; this makes analysis of an unknown sample very straightforward. We conclude that our approach could be employed as a simple method for the detection of minimal residual disease in B-precursor ALL, and unlike many other methods should prove applicable to virtually all cases of this malignancy.
Introduction
Childhood acute lymphoblastic leukemia (ALL) is highly sensitive to chemotherapy. Nearly all patients achieve complete remission following induction therapy and the majority are eventually cured. However, nearly a third of the patients in remission subsequently relapse, and most of these patients ultimately die of their disease. [1] [2] [3] [4] Recurrences are thought to stem from cells of the original leukemic clone. 5, 6 Following initial therapy, the disease is considered to be in hematologic remission when fewer than 5% of the cells in bone marrow samples are morphologically identifiable blasts. However, patients in remission may harbor as many as 10 9 -10 10 residual leukemic cells which are not detectable by conventional morphologic methods. Several studies have suggested that the rate of disappearance of blasts, as estimated by the blood blast cell count at day 8 and the marrow blast cell count at days 14-15 following the beginning of therapy, may help predict unfavorable outcome in patients with acute leukemia. [7] [8] [9] Thus, the assessment of minimal residual disease (MRD) during remission may help to evaluate the efficacy of therapy, predict impending relapse, and ultimately, permit early intervention in patients at high risk for relapse.
Several methods have been developed to detect and quantify MRD early in the course of ALL. Use of the polymerase chain reaction (PCR) to identify fusion transcripts and clonal antigen-receptor gene rearrangements is attractive because of its high sensitivity (1 leukemic cell per 10 3 -10 6 cells) when appropriately performed. 5, 10, 11 However, some PCR methods which use primers which hybridize to consensus sequences in the Ig or TCR gene are relatively insensitive and not informative in all cases. 12, 13 By contrast, more sensitive methods which use allele-specific probes prepared by sequencing amplified DNA from the original leukemic clones are much more expensive and labor intensive, 5, 14 and may not be applicable in all cases due to nonspecific hybridization with normal marrow cells or clonal evolution of the leukemia at relapse. 15 In addition, studies utilizing this technique have yielded inconsistent results with regard to the proportion of children harboring detectable residual disease during treatment and the correlation of submicroscopic leukemia with outcome. 1, 5, 10, 11, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] An alternative method for detecting MRD is the use of multiparameter flow cytometry. 11, [32] [33] [34] [35] [36] This technique exploits the fact that leukemic blasts often display 'aberrant' antigenic phenotypes; that is, cells express combinations of surface and cytoplasmic antigens different from those seen in normal marrow cells. 11, [33] [34] [35] [37] [38] [39] This approach has been used most extensively in AML and T-ALL, where the sensitivity of detection of aberrant cells approaches 1 in 10 000. 1, 11, [34] [35] [36] [38] [39] [40] [41] One limitation of flow cytometric analysis is that, with the exception of T-ALL, only a limited number of patients can be studied because the proportion of patients with 'leukemia specific' phenotypes is limited. This has been particularly true of B-precursor ALL, because normal B cell precursors (so-called hematogones) have phenotypes that are qualitatively similar to those which characterize leukemic blasts. Specifically, CD10
+

TdT
+ B cell precursors are seen in normal bone marrows and also may be increased in the marrows of patients following chemotherapy. [42] [43] [44] [45] [46] However, leukemic blasts frequently express these and other antigens at intensities which differ from those of normal cells; 42, 47, 48 normal hematogones demonstrate a distinctive pattern of differential expression of antigens with maturation, and this pattern is maintained in situations in which hematogones are increased. [43] [44] [45] [46] In this study we report a strategy that uses four-color flow cytometry and a limited antibody panel to rapidly and reliably distinguish B-precursor ALL from normal B cell precursors. Our study indicates that this method is applicable to essentially all cases of leukemia, and is relatively simple with minimal technical demands and straightforward analysis.
Patient samples
Cells were obtained from bone marrow specimens from patients undergoing clinically indicated bone marrow aspiration. Since our laboratory serves as the reference laboratory for immunophenotypic classification for the POG ALinC16 studies, we used excess material from these marrow samples to test a series of B-precursor ALL. Approval was obtained from the POG Cell Bank Committee for use of this material. The leukemic samples chosen were unselected, although the requirement for excess material may have introduced a slight bias. However, the great majority of specimens was adequate for study. Non-neoplastic bone marrow specimens were selected from discarded material received in the clinical flow cytometry laboratory for routine testing, and mostly consisted of negative staging marrows in patients with non-Hodgkin lymphoma or patients with acute myeloid leukemia in clinical remission. None of these samples were from patients with a history of B-precursor ALL. The specimens were selected to contain detectable levels of normal B cell precursors in the range of 2-10% of cells.
Immunofluorescence staining procedure
Marrow samples were processed by a whole marrow lysis technique. After a 5 min period of incubation with rabbit immunoglobulins (Dako, Burlingame, CA, USA) to block Fc receptors, the cell suspensions (Ȱ5 × 10 6 /ml) were incubated with fluorochrome-conjugated monoclonal antibodies at room temperature in the dark for 20 min. Selected antibodies were conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP) and allophycocyanin (APC) fluorochromes. Specimens were lysed with a proprietary lysing reagent (BD lyse; Becton Dickinson, San Jose, CA, USA) and washed twice in phosphate-buffered saline containing 0.5% bovine serum albumin and 0.2% sodium azide (PBSA). After centrifugation, the cell pellet was resuspended in a mixture of PBSA and 1.0% paraformaldehyde prior to flow cytometry. Antibodies were from Becton Dickinson and were used at concentrations titrated for optimal staining. In initial experiments, murine isotype-matched antibodies were included in the protocols as negative controls, although once patterns of antigen expression were identified, these were no longer routinely employed.
Specimens were analyzed on a BDIS FACSCalibur automated flow cytometry system (Becton Dickinson). Calibration beads (Calibrite; BD) were routinely used for monitoring and optimizing the instrument settings, and day-to-day reproducibility of instrument settings further ensured using QC3 beads (Flow Cytometry Standards Corporation, San Juan, Puerto Rico). For quality assurance, instrument maintenance was performed when either set of beads fell outside predefined limits provided the beads could be verified as performing appropriately (usually by testing on another instrument). List mode data files were acquired with the CellQuest software (BD) and gated acquisition was performed on displays of CD19 vs RALS such that a minimum of 20 000 CD19 + lymphoid cells were selectively recorded. Data analysis was initially performed using PAINT-A-GATE software, although in subsequent experiments it became apparent the Cell Quest software permitted the definitions of a fixed series of complex gates that could more effectively be used to compare normal and leukemic samples (see below).
In some experiments, mononuclear cells from patient samples previously shown to contain Ͼ90% blasts were isolated from the bone marrow specimens by density gradient centrifugation (Lymphoprep; Nycomed, Oslo, Norway) and washed twice in PBSA. These cells were then serially diluted into non-neoplastic specimens which contained increased normal B cell precursors. Dilutions ranged from 1:10 to 1:10 000, and the hybrid samples were coded and subjected to the same four-color analysis described above. An undiluted sample was analyzed by the standard method and examined to identify the characteristics of the abnormal population. Subsequently, results of each diluted analysis were scored as positive or negative without regard to knowledge of the dilution.
Results
Immunophenotypic characterization of normal B cell precursors
A series of 20 non-neoplastic marrows was stained with the four-color antibody combination CD19-APC/CD45-perCP/ CD20-PE/CD10-FITC. List mode data on approximately 20 000 CD19 + events were collected, and data were displayed on dual parameter dot plots. For the first five non-neoplastic samples, dual parameter dot plots of each antigen paired against each other antigen, or each antigen paired against forward and orthogonal light scatter were displayed and shapes of the characteristic dot plots were examined. A set of nine dot plots were determined to be most informative, based on the presence and degree of changes in the relative expression of one parameter against another during B cell differentiation. Polygonal regions were drawn around the displayed events on these dot plots ( Figure 1) ; the set of nine plots with defined regions is referred to as a template.
Once the template was created, it was used to examine list mode data from an additional series of 10 non-neoplastic marrows. Analysis of these 10 cases demonstrated three marrow specimens each of which contained a small cluster of events with a CD19
− phenotype. This subset of events deviated from the regions defined on the initial template. After the template was adjusted to reflect this distribution, the remaining 15 cases of normal B cell precursors fell completely within the newly defined regions. Figure 1 illustrates a nonneoplastic marrow analyzed with the final template.
To further characterize the immunophenotype of normal B cell precursors, a series of 19 non-neoplastic marrows was stained with the second four-color antibody combination CD19-APC/CD45-perCP/CD9-PE/CD34-FITC. Again, the list mode data on approximately 20 000 CD19 + events were collected and displayed on dual parameter dot plots. Nine dot plot regions were defined as described above, and a second template representing the immunophenotypic profile of normal hematogones was generated based on the first five cases. All remaining cases fell within the bound regions defined in this template (Figure 2 ).
It should be noted that over time there were slight shifts in the absolute, although not relative position of some populations such that the shape of the polygonal regions did not change; small adjustments could easily be made in the template to encompass all normal cells (data not shown). To further assess this variability we quantitatively compared mean channel fluorescence between lots of antibodies for a
Figure 1
Four-color flow cytometric analysis of normal B cell precursors. A bone marrow with normal B precursors was stained with the antibody combination CD19/CD45/CD20/CD10 and only CD19 + events acquired as described in the text. We refer to the irregular regions defined on the various displays as the template, and it can be seen that with the exception of isolated single events of uncertain nature, all normal B cell precursors fall within the boundaries of the normal template.
number of fluorochrome conjugates. There was no significant difference between mean CD10-FITC expression or mean CD45-perCP fluorescence when antibody lots were changed. In the case of CD9-PE, there was a very slight but statistically significant change in fluorescence when a new lot was employed, with a mean fluorescence intensity (MFI) of 557 ± 23 in the first lot and 588 ± 21 in the second (P Ͻ 0.04, Student's t-test). Thus, for most antibodies used the fluorescent variability is small and unlikely to materially effect our ability to use this methodology; as a precaution, however, we nonetheless check new lots of antibody against a normal marrow to ensure that the template remains stable. CD19-APC, by contrast, showed greater lot-to-lot fluorescence intensity variability, with MFI of 590 ± 17 in one lot and 638 ± 15 in another (P Ͻ 0.0001). While knowledge of intensity of CD19 is important for setting boundaries for the acquisition gate, it was not particularly important in the template, so instability in this parameter does not present a significant problem.
Immunophenotypic characterization of B-precursor ALL
A total of 82 cases of known B-precursor ALL was stained with the four-color antibody combination CD19-APC/CD45-perCP/CD20-PE/CD10-FITC. List mode data of these leukemic marrows were analyzed using the first template of defined regions generated from the immunophenotypic characterization of normal hematogones. Of these, 76 (93%) showed that at least 50% of the cluster of events representing the leukemic population extended outside the template's defined regions on one or more of the dual parameter displays (Figure 3 ). The
Figure 2
Four-color flow cytometric analysis of normal B cell precursors. A bone marrow with normal B precursors was stained with the antibody combination CD19/CD45/CD9/CD34 and only CD19 + events acquired. As in Figure 1 , all normal B cell precursors fall within the boundaries of the normal template save for isolated events of uncertain nature. most informative displays varied from case to case, and interpretation required visual inspection of all the displays to detect an abnormal leukemic phenotype. The displays which were most informative are listed in Table 1A . The remaining six leukemic marrows were completely within the template, or showed only small clusters of events extending outside the template, suggesting that the phenotypes of these cases were not significantly distinct from the phenotypes of normal hematogones.
A similar analysis was carried out with the second antibody combination: CD19-APC/CD45-perCP/CD9-PE/CD34-FITC. Seventy-seven of the same 82 cases of known B-precursor ALL were analyzed using the second template. Of these 77 cases, 72 (94%) fell outside the set of defined normal regions. The displays which were most informative with this analysis are listed in Table 1B . Importantly, 5/6 cases that had a normalappearing, or equivocally abnormal immunophenotypic profile on the first template, had a definitively abnormal profile on the second. Thus, overall, 81/82 (99%) cases of B-precursor ALL had detectable phenotypic abnormalities when studied by four-color flow cytometry as we describe. An example of a case of leukemia that was uninformative with the CD19/45/20/10 combination of antibodies but which was abnormal with the CD19/45/9/34 combination is illustrated in Figures 4 and 5 .
Sensitivity analysis
Sensitivity of this technique was tested by serially diluting Ficolled blasts into normal bone marrow samples and evaluating for the presence of an abnormal population. For each dilution, list mode data on 20 000 CD19 + events were collected. Figure  6 shows a detail of one informative dual parameter dot plot comparing the phenotype of a normal marrow with the phenotype of a 1:10 000 dilution of leukemic blasts into the
Figure 3
Four-color flow cytometric analysis of B-precursor ALL stained and analyzed as in Figure 1 . There are a few residual normal mature and immature B cells which appear as a distinct cluster within the normal template, but the majority population of leukemic cells are readily distinguishable as falling outside it. Note that certain dual parameter displays are more informative than others, that is, on some displays (such as CD19 vs CD10) the population is not much different from normal, while on others (such as CD45 vs CD10 or forward scatter vs CD20) the leukemic population is clearly abnormal. 16 (21) same normal marrow. The abnormal cells are readily detected as a distinct cluster of events in the same relative distribution seen in the initial non-diluted leukemic sample (not shown).
We computed the number of events in this cluster and found that they accounted for 0.012% of cells in the sample, in excellent agreement with the dilution factor. Note that the few isolated events outside the region on the normal sample, but not forming a discrete cluster, are not interpreted as 'positive'. The striking difference in the appearance of the discrete cluster compared to the nonspecific scattered events was highly reproducible in these dilution experiments.
To provide a more rigorous test for the sensitivity measurements, leukemic blasts were next diluted into a non-neoplastic marrow containing a significant increase (approximately 10%) of normal B cell precursors. Under this circumstance, a sensitivity level of only 1:1000 cells could be achieved when
Figure 4
Four-color flow cytometric analysis of B precursor ALL stained and analyzed as in Figure 1 . Note that although leukemic cells are beyond the margins of normal, the majority of cells are within the normal area. This would potentially make it difficult to detect very small numbers of such cells in the presence of normal B cell precursors.
000 CD19
+ events were collected. To try to improve sensitivity, the experiment was repeated by diluting leukemic blasts into a different sample containing about 20% normal B cell precursors, and processing a total of about 10 6 cells (or about 200 000 CD19 + cells). Figure 7 illustrates that blasts are detectable with a sensitivity of 1:10 000 in the presence of 20% normal B cell precursors provided that sufficient CD19 + cells are examined to have the abnormal cells form a discrete cluster.
Discussion
In this study we demonstrate that there are quantitative differences in the relative intensities of surface antigen expression and light scatter properties between normal hematogones and leukemic cells in virtually all cases of B-precursor ALL, and that these differences can be detected with four-color fluorescence flow cytometry without requiring assembly of large panels of antibodies. This work is an extension of previous investigations which utilized two-and three-color immunofluorescence to demonstrate that hematogones have a predictable pattern of acquisition of B cell differentiation antigens. [43] [44] [45] [46] [47] [48] Although these prior studies elucidated the phenotypic patterns of normal and regenerating marrows, they did not explore the phenotypic differences between hematogones and leukemic blasts.
The analytical approach we developed relies on the generation of fixed templates of dual parameter displays representing non-neoplastic specimens, and then superimposing on these stored templates list mode files of leukemias and unknown specimens. Although other methodologies, such as the application of the PAINT-A-GATE software or Boolean gating could be employed to identify normal and abnormal cell populations, our technique is fairly straightforward and allows for visual interpretation once the templates are created. Criti-
Figure 5
Same case as Figure 4 stained with the combination CD19/CD45/CD9/CD34 and analyzed with a template defined by studying normals. Note that on several displays (arrows) the population is almost entirely outside the boundaries of the normal template which would greatly facilitate detection of MRD. cal to the utility of our technique was the strategic assembly of antibody panels which optimally enhance the phenotypic differences between hematogones and leukemic blasts. In each of the two panels we employed CD19 as a common reagent to permit selective gating on CD19 + B cells without overwhelming the analytical capacity of the flow cytometer. Second, CD45 was also used as a common reagent because of its previously demonstrated power to distinguish ALL blasts from normal cells. 45, 49, 50 Thus, with the templates generated from the two-tube antibody combinations CD19-APC/CD45-perCP/CD20-PE/CD10-FITC and CD19-APC/CD45-perCP/ CD9-PE/CD34-FITC, we were able to identify an abnormal immunophenotype in 99% (81/82) of the cases of B-precursor ALL analyzed. The most striking phenotypic differences between leukemic blasts and normal hematogones were the expression of CD45 relative to either CD10 or CD34; the expression of forward scatter (FSC) relative to CD34, CD20 and CD10; and the expression of CD34 relative to CD9 (Table 1) .
Despite the straightforward nature of our technique, an accurate interpretation of the results requires a potentially subjective evaluation of the distribution of events. Specifically, we often encountered small numbers of events which fell outside the defined normal regions of the template (see Figure 1) . Although this obviously is of little consequence in the evaluation of de novo leukemias, it has important implications for the application of this technique to the study of minimal residual disease. However, review of the phenotypic patterns seen in leukemia revealed that unlike these isolated events abnormal cells always formed discrete clusters of events falling outside the normal template; acquiring more events could enhance this clustering phenomenon. In spite of this, until this technique is applied to clinical samples it is uncertain to what extent this may be a problem. If such samples pose difficulties,
Figure 6
Four color flow cytometric analysis of a specimen of leukemia diluted 1/10 000 into normal bone marrow and stained as described in Figure 5 . Note the distinct cluster of leukemic cells not present on the normal sample without leukemia. This cluster is in the exact position seen in the undiluted leukemia (not shown). There are scattered isolated normal events outside the template, but these do not form a cluster, and are not in this area, and would not be interpreted as positive.
Figure 7
Four-color flow cytometric analysis of a specimen of leukemia diluted 1/10 000 into a bone marrow containing 20% normal B cell precursors, and stained and analyzed as in Figure 6 , except that 10-fold more CD19 + events were collected. Note the cluster of abnormal leukemic cells (large arrow) which is clearly outside the normal template and can be readily detected at this level. Note also that with this many normal cells, templates drawn based on acquiring fewer events are not precisely accurate (see short arrow). This indicates that in the presence of large numbers of normal B cell precursors, slight differences in phenotype between leukemias and normals (such as illustrated in Figure 4 ) may not be appropriate for residual disease monitoring.
it may be that comparison to the pattern seen diagnostically may be necessary to determine the presence of residual disease.
The impact that residual disease may have on therapy and prognosis is largely dependent on the sensitivities of the methods used to detect abnormal cells. Some recent studies have shown that a level of detection of 10 −4 carries a strong predictive value, 51 while others suggest that clinical significance is found at a level as high as 10 −2 . 52 To assess the utility of our technique for the detection of residual disease, we performed a series of dilution experiments combining leukemic blasts with normal, non-neoplastic marrow specimens. Our technique was subjected to a stricter test by selecting these 'normal' specimens to contain increased numbers of normal B cell precursors, as the ability to detect abnormal B cells is directly related to the number of normal B cells in the background. This sensitivity analysis demonstrated that leukemic blasts diluted into either normal marrow or marrow with increased hematogones could easily be detected at a level of 1/1000 cells with both antibody combinations in each case, and could also be seen at a 1/10 000 dilution in normal marrow.
Flow cytometry, generally employing two-and three-color analysis, has been used for detecting minimal residual disease in patients with leukemia. Most of these studies have been based on the detection of cells expressing combinations of antigens not present on normal cells. 1, 11, [34] [35] [36] [37] [38] [39] Although essentially all T-ALL express abnormal phenotypes, 1 B-precursor ALL has provided more of a challenge because of the known similarities between leukemic phenotypes and those of normal B cell precursors. 42, 47, 48 Orfao et al 53 were able to distinguish normal and leukemic B cell precursors on the basis of myeloid antigen expression, but found that only 55% of a series of 56 patients had informative phenotypes. Vervoordeldonk et al 32 employed a different strategy in a small series of 15 patients by defining an upper limit for the number of positive cells that could be present in normals. However, their analysis included only CD34
+ cases and the sensitivity of their analysis was limited because 10-30% of the CD34 + cells with their defined abnormal phenotypes could also be identified in patients without leukemia. Recently, Coustan-Smith et al 1 have used flow cytometry to monitor aberrant phenotypes to show that the MRD was an important prognostic factor in clinical outcome in a series of 150 children with ALL, but fewer than 60% of their patients had informative phenotypes, and their series included both T-and B-precursor ALL patients.
To overcome the problem with normal B cell precursors, Farahat et al 48 employed a quantitative procedure to assess various antigen intensities and demonstrated that in almost all cases of B-lineage ALL, the blasts had lower numbers of TdT molecules and higher numbers of CD10 molecules than did their normal counterparts. Our strategy, which takes advantage of the multiparameter nature of flow cytometric technology, relies on detecting similar quantitative rather than qualitative differences between normal and neoplastic cells, but has the advantage that it does not require precise quantitation.
There is an increasing body of literature that residual disease detection, particularly early in remission when therapeutic interventions are possible, may be of prognostic significance in ALL. 1, 5, [7] [8] [9] [10] [11] [12] [13] [14] [18] [19] [20] [24] [25] [26] [27] 32, 52 . The strategy we describe here may not only be suitable for MRD studies, but may also be superior to other technologies currently employed for detecting and monitoring residual disease. Our technique appears to be informative in a much higher percentage of cases than most current flow cytometric approaches, and simpler to perform than many of the molecular strategies which require creation of clone-specific probes. Although it is less sensitive than the latter approach, it remains to be determined if the added sensitivity afforded by molecular techniques is of clinical significance. Indeed, in a recent study of MRD in ALL by Cave et al 52 the best predictor for treatment failure was at a level of about 1/100 blast cells. Future studies will address the feasibility of our flow cytometric approach in the study of a cohort of children with B-precursor ALL, and will determine if MRD detected by our method is an independent prognostic factor in clinical outcome.
